Safety and efficacy of eculizumab in the prevention of antibody‐mediated rejection in living‐donor kidney transplant recipients requiring desensitization therapy: A randomized trial

We report results of a phase 2, randomized, multicenter, open‐label, two‐arm study evaluating the safety and efficacy of eculizumab in preventing acute antibody‐mediated rejection (AMR) in sensitized recipients of living‐donor kidney transplants requiring pretransplant desensitization (NCT01399593)....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Am J Transplant
Main Authors: Marks, William H., Mamode, Nizam, Montgomery, Robert A., Stegall, Mark D., Ratner, Lloyd E., Cornell, Lynn D., Rowshani, Ajda T., Colvin, Robert B., Dain, Bradley, Boice, Judith A., Glotz, Denis
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2019
Assuntos:
ORIGINAL ARTICLES
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6790671/
https://ncbi.nlm.nih.gov/pubmed/30887675
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ajt.15364
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados